FAP and neoplasm: Although several novel FAP-targeting radiotherapeutic agents have been developed, such as [90Y]Y-FAPI-04 [26], [177Lu]Lu-DOTA.SA.FAPi [28], and [177Lu]Lu-FAPI-46 [29], their tumor-retention time and efficacy in clinical investigation have been disappointing.